Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 22, 2026TH OpenOpen Access

Provided text consists solely of an editorial board list and contains no clinical findings.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Guideline-recommended indefinite DOAC therapy after successful AF ablation is challenged by bleeding risks versus potentially reduced stroke risk post-ablation.

Does DOAC discontinuation reduce bleeding without increasing thromboembolic events in patients with no documented AF recurrence for ≥1 year after catheter ablation?

Population

2124 patients with no documented AF recurrence for ≥1 year after ablation

Comparison

DOAC continuation vs DOAC discontinuation

Design

Meta-analysis of trials

Key result

The provided text consists solely of an editorial board list and contains no clinical trial results or findings.

Authors

WCW ChengYCYi‐Hsin ChanLKLing Kuo

Discussion

Loading...

Member takes

Overview

Supports DOAC discontinuation after successful AF ablation to reduce bleeding; extends RCT evidence with no rise in thromboembolic events.

Key Points

  • This study aimed to compare long-term antithrombotic strategies in patients without atrial fibrillation recurrence after catheter ablation.
  • Conducted a meta-analysis of the ALONE-AF and OCEAN trials involving 2124 patients.
  • Compared outcomes of direct oral anticoagulant (DOAC) continuation versus discontinuation.
  • Calculated pooled risk ratios for thromboembolic events, mortality, and bleeding events.
  • No statistically significant difference in thromboembolic events or mortality rates between DOAC continuation and discontinuation.
  • DOAC continuation linked to a higher risk of major bleeding (RR 3.07; 95% CI: 1.05-8.96).
  • DOAC discontinuation lowered the risk of bleeding without increasing stroke risk.

Study Design

Type

Meta-Analysis

Structured PICO

Does DOAC discontinuation reduce bleeding without increasing thromboembolic events in patients with no documented AF recurrence for ≥1 year after catheter ablation?

P
Population
2124 patients with no documented atrial fibrillation recurrence for ≥1 year after catheter ablation (pooled from ALONE-AF and OCEAN trials)
I
Intervention
Direct oral anticoagulant (DOAC) discontinuation
C
Comparator
Direct oral anticoagulant (DOAC) continuation
O
Outcome
Primary efficacy (thromboembolic events/all-cause mortality) and safety (bleeding events)composite

Discontinuing DOACs in patients free from AF for at least one year post-ablation significantly reduces bleeding risk without increasing thromboembolic events.

Cite This Study

Cheng et al. (2026) conducted a meta-analysis in Atrial Fibrillation. Antithrombotic Management was evaluated. The provided text consists solely of an editorial board list and contains no clinical trial results or findings.

synapsesocial.com/papers/6a605ea14163e025518d8654https://doi.org/10.1055/a-2916-8912
View Full Paper
Ask AI
Bookmark
Share